AGC Biologics, the world's leading contract research and manufacturing organization (CDMO), announced the addition of three new Grade B cell therapy manufacturing facilities at its Longmont, Colorado, facility to improve manufacturing capacity.

The addition of AGC Biologics Longmont includes two new Process Suites and one Flex Suite to expand the responsiveness of the Colorado facility. The expanded space of more than 2,1 square feet includes multiple isolation rooms that handle a wide variety of products. The cleanroom has a state-of-the-art modular design with flexible capacity configurations, and state-of-the-art cell therapy manufacturing equipment supports open and closed processes to produce autologous and allogeneic cell therapies.

The three new cell therapy manufacturing facilities expand the company's manufacturing capabilities for gene and cell therapy services at its North American location. This allows AGC Biologics Longmont to provide end-to-end development and manufacturing services for cell therapies in one place. The new lab expands the facility's manufacturing capabilities and complements the facility's robust viral vector development and manufacturing services, providing unique benefits for developers looking for a place to provide comprehensive services in one place for bringing their products to market. Other key features include early-stage process development support, commercial manufacturing, quality control and analysis, filling and final formulation services, and on-site warehousing. With ample space at the Longmont campus, AGC Biologics will be able to add nine more cell therapy manufacturing facilities to meet emerging market demand.

"We have integrated the latest technologies to complete our unique cell therapy services and create the perfect environment to develop life-changing therapies," said Whitney Sandberg, General Manager of AGC Biologics Colorado. "This is the final piece of creating a campus with comprehensive viral vector capabilities, providing developers with an end-to-end manufacturing location in North America to help them with everything they need for a product at every stage."

AGC Biologics acquired the Longmont campus in August 2021. Scientists at the facility have more than 8 years of experience working on complex cell therapies and viral vector products and substances.

AGC Biologics is an end-to-end global viral vector and cell therapyWe provide development, manufacturing, quality control and regulatory services. The company's team supports clinical trials of four commercial viral vector products, three commercial cell therapies, and more than 4 cell and gene therapies in Europe and the United States. The Contract Research and Manufacturing Organization (CDMO) operates two facilities above Grade C, one each in Milan and Longmont. Supported by scientists with more than 3 years of knowledge and experience, the company uses the latest technologies and platforms to help develop the growing market for advanced therapeutics.

This year, AGC Biologics announced an official patent platform for lentiviral vector manufacturing and adeno-associated viral vector production, complementing the world's prontoLVV and BravoAAV ™ ™ gene and cell therapy services.